|
[1]HUNDT M, JOHN S.Physiology, Bile Secretion[M].Stat Pearls Publishing, 2018.
|
|
[2]BOYER JL.Bile formation and secretion[J].Compr Physiol, 2013, 3 (3) :1035-1078.
|
|
[3]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.
|
|
[4]LI T, CHIANG JY.Bile acid signaling in metabolic disease and drug therapy[J].Pharmacol Rev, 2014, 66 (4) :948-983.
|
|
[5]SHAH R, JOHN S.Jaundice, Cholestatic (Cholestasis, Cholestatic Hepatitis) [M].Stat Pearls Publishing, 2018.
|
|
[6]POLLOCK G, MINUK GY.Diagnostic considerations for cholestatic liver disease[J].J Gastroenterol Hepatol, 2017, 32 (7) :1303-1309.
|
|
[7]SLIJEPCEVIC D, van de GRAAF SF.Bile acid uptake transporters as targets for therapy[J].Dig Dis, 2017, 35 (3) :251-258.
|
|
[8]SLIJEPCEVIC D, ROSCAM ABBING RLP, KATAFUCHI T, et al.Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice[J].Hepatology, 2017, 66 (5) :1631-1643.
|
|
[9]STICOVA E, JIRSA M, PAWOWSKA J.New insights in genetic cholestasis:From molecular mechanisms to clinical implications[J].Can J Gastroenterol Hepatol, 2018, 2018:2313675.
|
|
[10]LI T, APTE U.Bile acid metabolism and signaling in cholestasis, inflammation, and cancer[J].Adv Pharmacol, 2015, 74:263-302.
|
|
[11]VAZ FM, PAULUSMA CC, HUIDEKOPER H, et al.Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency:Conjugated hypercholanemia without a clear clinical phenotype[J].Hepatology, 2015, 61 (1) :260-267.
|
|
[12]HAGENBUCH B, STIEGER B.The SLCO (former SLC21) superfamily of transporters[J].Mol Aspects Med, 2013, 34 (2-3) :396-412.
|
|
[13]TTH B, JANI M, BERY E, et al.Human OATP1B1 (SLCO1B1) transports sulfated bile acids and bile salts with particular efficiency[J].Toxicol In Vitro, 2018, 52:189-194.
|
|
[14]THOMSON MM, HINES RN, SCHUETZ EG, et al.Expression patterns of organic anion transporting polypeptides 1B1 and1B3 protein in human pediatric liver[J].Drug Metab Dispos, 2016, 44 (7) :999-1004.
|
|
[15]THAKKAR N, SLIZGI JR, BROUWER KLR.Effect of liver disease on hepatic transporter expression and function[J].JPharm Sci, 2017, 106 (9) :2282-2294.
|
|
[16]NIGAM SK, BUSH KT, MARTOVETSKY G, et al.The organic anion transporter (OAT) family:A systems biology perspective[J].Physiol Rev, 2015, 95 (1) :83-123.
|
|
[17]SLOPIANKA M, HERRMANN A, PAVKOVIC M, et al.Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats[J].Toxicology, 2017, 386 (7) :1-10.
|
|
[18]WAGNER DJ, HU T, WANG J.Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics[J].Pharmacol Res, 2016, 111:237-246.
|
|
[19]ZOLLNER G, WAGNER M, FICKERT P, et al.Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis[J].Liver Int, 2007, 27 (7) :920-929.
|
|
[20]MEMON N, WEINBERGER BI, HEGYI T, et al.Inherited disorders of bilirubin clearance[J].Pediatr Res, 2016, 79 (3) :378-386.
|
|
[21]SOROKA CJ, BOYER JL.Biosynthesis and trafficking of the bile salt export pump, BSEP:Therapeutic implications of BSEP mutations[J].Mol Aspects Med, 2014, 37 (2) :3-14.
|
|
[22]RIEDE J, POLLER B, HUWYLER J, et al.Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations[J].Drug Metab Dispos, 2017, 45 (5) :523-531.
|
|
[23]YU XH, QIAN K, JIANG N, et al.ABCG5/ABCG8 in cholesterol excretion and atherosclerosis[J].Clin Chim Acta, 2014, 428 (2) :82-88.
|
|
[24]FERRIGNO A, DI PASQUA LG, BERARDO C, et al.The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury[J].PLo S One, 2018, 13 (1) :e0191430.
|
|
[25]TARDELLI M, CLAUDEL T, BRUSCHI FV, et al.Nuclear receptor regulation of aquaglyceroporins in metabolic organs[J].Int J Mol Sci, 2018, 19 (6) :e1777.
|
|
[26]PENG H, ZHU QS, ZHONG S, et al.Transcription of the human microsomal epoxide hydrolase gene (EPHX1) is regulated by PARP-1 and histone H1.2.association with sodiumdependent bile acid transport[J].PLo S One, 2015, 10 (5) :e0125318.
|
|
[27]KEPPLER D.Cholestasis and the role of basolateral efflux pumps[J].Z Gastroenterol, 2011, 49 (12) :1553-1557.
|
|
[28]HALILBASIC E, CLAUDEL T, TRAUNER M.Bile acid transporters and regulatory nuclear receptors in the liver and beyond[J].J Hepatol, 2013, 58 (1) :155-168.
|
|
[29]CHEUNG AC, LORENZO PISARELLO MJ, LARUSSO NF.Pathobiology of biliary epithelia[J].Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1220-1231.
|
|
[30]LI XF, GONG JY, WANG JS.Association between enterohepatic circulation of bile acid and cholestatic liver disease[J].JClin Hepatol, 2017, 33 (10) :1922-1927. (in Chinese) 李晓峰, 龚敬宇, 王建设.胆汁酸的肠肝循环与胆汁淤积性肝病[J].临床肝胆病杂志, 2017, 33 (10) :1922-1927.
|
|
[31]BAGHDASARYAN A, FUCHS CD, STERREICHER CH, et al.Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis[J].J Hepatol, 2016, 64 (3) :674-681.
|
|
[32]HAMOUD AR, WEAVER L, STEC DE, et al.Bilirubin in the livergut signaling axis[J].Trends Endocrinol Metab, 2018, 29 (3) :140-150.
|
|
[33]LU LG.Hotspots and difficulties of clinical and basic research in cholestatic liver disease[J].Chin J Hepatol, 2015, 23 (8) :561-563. (in Chinese) 陆伦根.胆汁淤积性肝病临床和基础研究热点和难点[J].中华肝脏病杂志, 2015, 23 (8) :561-563.
|
DownLoad: